Constellation Pharmaceuticals Inc (CNST)stock report

Constellation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. The Company is primarily if focused on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression and drug resistance. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-1205, and the other program is evaluating a compound, CPI-0610.

Finance:
Q3 2019(9/30/19): Cash 89.07M. Loss 21.15M

EPS and Sales:
https://finance.yahoo.com/quote/CNST/financials?p=CNST

Date EPS % last year % last quarter
2018.12.31 -5 91.09% -8.26%
2019.3.31 -0.75 93.97% 85.00%
2019.6.31 -1.56 92.95% -6.00%
2019.9.30 -2.38 56.33% -52.56%

 

Sale:0

Insider Transactions:
http://insidercow.com/history/company.jsp?company=CNST&B1=Search%21

Institution Ownership:
https://www.marketbeat.com/stocks/NYSE/CNST/institutional-ownership/

2019.12.03:
Total institutions: 56,no change
Shares hold: 20670.8k shares. no change
shares% hold: 61.64%,no change

Analyst Ratings:
https://www.tipranks.com/stocks/CNST/price-targe

Leave a Reply

×